Liraglutide

Liraglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. The molecule shares 97% amino acid sequence homology with endogenous GLP-1 but carries a C-16 fatty acid (palmitic acid) attached via a glutamic acid spacer to a lysine residue. This modification enables reversible albumin binding and resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase, extending the plasma half-life to approximately 13 hours and supporting once-daily subcutaneous dosing.

Binding to GLP-1 receptors on pancreatic beta-cells activates adenylate cyclase, raising intracellular cyclic AMP (cAMP) and stimulating glucose-dependent insulin secretion. Because insulin release is glucose-dependent, intrinsic hypoglycemia risk is low when the drug is used without concurrent insulin or sulfonylureas. Liraglutide concurrently suppresses glucagon secretion from pancreatic alpha-cells, reducing hepatic glucose output and attenuating postprandial glycemic excursions.

GLP-1 receptors are also expressed in hypothalamic and brainstem nuclei that regulate energy homeostasis. Central receptor activation reduces appetite, increases satiety, and decreases caloric intake. Liraglutide additionally slows gastric emptying, blunting postprandial glucose peaks. Together, these pancreatic, hepatic, and central actions underlie its dual regulatory approvals: as an antidiabetic agent (Victoza, approved January 2010) and as a chronic weight-management medication (Saxenda, approved December 2014).

Liraglutide has been evaluated in large phase 3 randomized controlled trials spanning glycemic control, cardiovascular risk reduction, and weight management.

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015; n=3,731; PMID 26132939) randomized non-diabetic adults with a BMI of 30 or higher, or 27 with at least one comorbidity, to liraglutide 3.0 mg daily or placebo plus lifestyle counseling for 56 weeks. Liraglutide produced a mean body weight reduction of 8.0% versus 2.6% with placebo (a between-group difference of approximately 5.6 kg; p<0.001). At least 5% weight loss was achieved by 63.2% versus 27.1% of patients (NNT=3), and at least 10% by 33.1% versus 10.6% (NNT=5). Secondary improvements included reductions in waist circumference (-8.2 vs. -3.9 cm), triglycerides (-13.3% vs. -5.5%), and systolic blood pressure (-4.2 vs. -1.5 mm Hg).

The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016; n=9,340; PMID 27295427) enrolled adults with type 2 diabetes at high cardiovascular risk and compared liraglutide (up to 1.8 mg daily) to placebo over a median follow-up of 3.8 years. The primary three-point MACE endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 13.0% of the liraglutide group versus 14.9% with placebo (HR 0.87; p=0.01 for superiority). Cardiovascular death was reduced from 6.0% to 4.7%. A 2020 JACC sub-analysis of LEADER found that cardiovascular benefit was consistent regardless of baseline heart failure status (18% of participants had pre-existing NYHA class I-III HF).

A pre-specified renal sub-analysis of LEADER (Mann et al., NEJM 2017; PMID 28854085) found a 22% relative risk reduction in a composite renal endpoint, driven primarily by fewer patients developing new-onset persistent macroalbuminuria (161 vs. 215). As a glycemic agent, liraglutide reduces HbA1c by up to approximately 1.1 percentage points as monotherapy in adults with type 2 diabetes.

Typical dosage: 0.6-3.0 mg (daily).

Liraglutide is marketed at two distinct dose ranges for separate indications, both via subcutaneous injection.

Victoza (type 2 diabetes mellitus, glycemic control and cardiovascular risk reduction; adults and pediatric patients aged 10 and older): • Week 1: 0.6 mg once daily (tolerability ramp-up; not a therapeutic glycemic dose) • Week 2 onward: 1.2 mg once daily • Optional escalation for additional glycemic control: 1.8 mg once daily • Maximum approved dose: 1.8 mg/day

Saxenda (chronic weight management in adults with BMI 30 or higher, or 27 or higher with at least one weight-related comorbidity; also approved for adolescents aged 12 years and older with obesity): • Week 1: 0.6 mg once daily • Week 2: 1.2 mg once daily • Week 3: 1.8 mg once daily • Week 4: 2.4 mg once daily • Week 5 onward (maintenance): 3.0 mg once daily • Maximum approved dose: 3.0 mg/day. If 3.0 mg cannot be tolerated, Saxenda should be discontinued, as lower doses have not demonstrated efficacy for weight management.

Injections are administered in the abdomen, thigh, or upper arm at any time of day, without regard to meals. Peak plasma concentrations are reached approximately 8 to 12 hours post-injection. The stepwise escalation schedule is intended to minimize gastrointestinal intolerance during initiation.

This information is provided for educational reference only and does not constitute medical advice. Liraglutide is a prescription-only medication; dosing, dose escalation decisions, and clinical appropriateness must be determined by a qualified healthcare provider.

Lyophilized (before reconstitution)

Refrigerate 2–8°C before first use. Do not freeze. Protect from light in the original carton.

Reconstituted

Victoza and Saxenda: after first use, the pen may be kept at room temperature (≤30°C) or refrigerated (2–8°C) for up to 30 days. Keep the pen cap on when not in use to protect from light.

For general storage chemistry (bacteriostatic vs sterile water, freeze-thaw, BUD framework), see Storage & handling.

Last reviewed: July 1, 2026

Liraglutide plus metformin is the most extensively studied combination for type 2 diabetes, with randomized trials and retrospective analyses demonstrating additive HbA1c reductions compared with metformin monotherapy (approximately -1.8% versus -1.3% in one retrospective study).

The LEAD-5 randomized controlled trial demonstrated that liraglutide added to existing metformin and sulfonylurea therapy produced superior glycemic and body weight outcomes compared with insulin glargine add-on.

Basal insulin analogues (e.g., insulin detemir) have been studied as add-on therapy to liraglutide plus metformin, with dedicated trials showing further HbA1c reductions and reduced insulin requirements without substantial increase in hypoglycemia risk.

Combination with SGLT2 inhibitors (e.g., canagliflozin) has been described in case reports and small observational series showing complementary mechanisms: appetite suppression and glucose-dependent insulin secretion from the GLP-1 agonist alongside urinary glucose excretion from the SGLT2 inhibitor. A 2022 case series (Capozzi et al., PMC8788265) reported marked HbA1c and weight reductions with high-dose liraglutide plus SGLT2 inhibitor, but the study comprised only two patients with no control group. Large randomized controlled trial data for this specific combination are absent; current evidence should be regarded as preliminary and largely anecdotal.

Liraglutide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Nausea, GI disturbances, potential pancreatitis

Gastrointestinal adverse effects are the most common class of side effects. In the SCALE trial, nausea occurred in 40.2% of liraglutide 3.0 mg patients versus approximately 15% on placebo; diarrhea (20.9%), constipation (20.0%), and vomiting (16.3%) were also more frequent. These effects are dose-dependent, typically emerge during dose escalation, and tend to attenuate with continued use.

Serious adverse events include:

• Medullary thyroid carcinoma (MTC): Liraglutide produces dose- and duration-dependent thyroid C-cell tumors in rats and mice; human relevance is undetermined. Six cases of C-cell hyperplasia were reported among liraglutide-treated trial participants versus 2 in comparators. The drug is absolutely contraindicated in patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN2). • Acute pancreatitis: Confirmed in 9 of 3,291 liraglutide-treated patients versus 1 of 1,843 placebo patients in obesity trials (incidence below 0.4%). • Gallbladder disease: Approximately 2.2% incidence in treated patients. • Renal impairment: Acute kidney injury has occurred, typically secondary to volume depletion from gastrointestinal effects. • Elevated resting heart rate: Increases of 4 to 9 beats per minute observed across trials. • Hypoglycemia: Low intrinsic risk as monotherapy due to glucose-dependent insulin secretion; risk is substantially elevated when combined with insulin or sulfonylureas. • Suicidal ideation: Reported in 0.3% of adults and 0.8% of pediatric patients per the FDA prescribing label. • Hypersensitivity reactions: Anaphylaxis and angioedema have been reported.

Liraglutide is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis. Safety in pregnancy has not been established; animal studies indicate fetal harm, and use during pregnancy is not recommended.